SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
AstraZeneca PLC (AZNCF) trades at a trailing P/E of 29.0, forward P/E of 18.5. Trailing earnings yield is 3.44%, forward earnings yield 5.42%. PEG 0.64 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (60/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.64).
- Forward P/E 18.5 (down from trailing 29.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.64 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.44% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.42% as earnings recover.
Overall SharesGrow Score: 69/100 with 5/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AZNCF
Valuation Multiples
P/E (TTM)29.0
Forward P/E18.5
PEG Ratio0.64
Forward PEG0.32
P/B Ratio0.00
P/S Ratio5.05
EV/EBITDA0.0
Per Share Data
EPS (TTM)$6.54
Forward EPS (Est.)$10.29
Book Value / Share$0.00
Revenue / Share$37.60
FCF / Share$0.00
Yields & Fair Value
Earnings Yield3.44%
Forward Earnings Yield5.42%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$2.76 |
$23B |
$3.5B |
15.2% |
| 2017 |
$2.37 |
$22.47B |
$3B |
13.4% |
| 2018 |
$1.70 |
$22.09B |
$2.16B |
9.8% |
| 2019 |
$1.07 |
$24.38B |
$1.34B |
5.5% |
| 2020 |
$2.59 |
$26.62B |
$3.2B |
12% |
| 2021 |
$0.08 |
$37.42B |
$112M |
0.3% |
| 2022 |
$2.07 |
$44.35B |
$3.29B |
7.4% |
| 2023 |
$3.81 |
$45.81B |
$5.96B |
13% |
| 2024 |
$4.50 |
$54.07B |
$7.04B |
13% |
| 2025 |
$6.54 |
$58.74B |
$10.23B |
17.4% |
